Decitabine (NSC 127716)

For research use only. Not for use in humans.

製品コードS1200 別名:Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

Decitabine (NSC 127716)化学構造

CAS No. 2353-33-5

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 27700
JPY 16900
JPY 30200
JPY 55100
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(130)

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MV7GeY5kfGmxbjDBd5NigQ>? MnqxNE42yqEQvF2= MX6yOEBp M1XzeJdifGW{ MnLxcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> M3rtNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 NWnwTXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTL[pMxNjVxMj61M|Uh|ryP M3PKTVI1NzR6L{eyJIg> M{n0dZdifGW{ M4e3e4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NHzYWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN|A5Oid-MkWxNlMxQDJ:L3G+
Eca109 NFT1dIpHfW6ldHnvckBCe3OjeR?= MkLINE42yqEQvF2= M4n5dFYwOTJxMkSgbC=> NFjNPXB4[XSnch?= NIPJNXZqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg MmHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NWOxXGV4TnWwY4Tpc44hSXO|YYm= NYWzSmNHOC53wrFOwG0> MlXsNlQhcA>? MkXme4F1\XJ? NHPDWVJqdmirYnn0d{Bk\WyuIHnueoF{cW:w MlriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NWnY[JIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzJdJcxNjYEoN88US=> NVnX[|JKOjRiaB?= MUL3ZZRmeg>? NUD2coxTcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? NVzFXZpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 MmjGSpVv[3Srb36gRZN{[Xl? NFTk[mYxNjVxMTFOwG0> NIK2d3AzPCCq MYT3ZZRmeg>? M{TjcYRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ? MoHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
SW1116  NYXqZWluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[xOVAvPS9zL{KvOUDPxE1? M2izNlQ5KGh? NUPxVFJYTE2VTx?= MVHlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u M{DXclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO NWK1e|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUW4TmpwOC53L{GvNk82KM7:TR?= MU[0PEBp NWTZbZZnTE2VTx?= MUXlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
SW1116  M1\YXWZ2dmO2aX;uJGF{e2G7 NHPlUXIyOCEQvF2= MmDlOFghcA>? MUnEUXNQ MlXObY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO M2r2[mZ2dmO2aX;uJGF{e2G7 NXXTU2NbOTBizszN M1z4flQ5KGh? M1rKRmROW09? NU\qWG5vcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk NYT6TJAxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
SW1116  M37SV2Fxd3C2b4Ppd{BCe3OjeR?= M3e0cFExKM7:TR?= NVvufYREPDhiaB?= MoDYSG1UVw>? M3vRZYVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> MlTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
LOVO MmHZRZBweHSxc3nzJGF{e2G7 MniyNVAh|ryP MUW0PEBp NYSwcVlyTE2VTx?= NWewWGNz\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226 MoSzRZBweHSxc3nzJGF{e2G7 MWWxM|Ih|ryP NYLTT|JmPDhxN{KvPVYhcA>? NHG3OVJFVVOR NYT6OoRPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3rCUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
OPM-2  NVXzZW9NSXCxcITvd4l{KEG|c3H5 NGSwUJUyNzJizszN NHHJXGM4Oi97Nj:xNlAhcA>? MYXEUXNQ NVrNTWk2cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NUKxfFJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
JJN3  M{nUVWFxd3C2b4Ppd{BCe3OjeR?= Mki0NE42NzFizszN MU[yOE81QCCq NELmWIZFVVOR NVvNVZBOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NYrKTYU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
NCI-H929  NVKzT5ppSXCxcITvd4l{KEG|c3H5 NGrMdYYyNzJizszN MUm3Nk86Pi9zMkCgbC=> MlzmSG1UVw>? NWnW[3pKcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M13vOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN|ExQDxxYU6=
RPMI-8226 NF\mXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLFNU8zKM7:TR?= NWnFfVU{OjRxNEivO|IhcA>? MWPEUXNQ Moe4ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? MorQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
OPM-2  NWjpZohYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nFb|EwOiEQvF2= MYiyOE81QC95MjDo NEXzSXdFVVOR M1nMNIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 Ml;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
JJN3  NEDZcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVewMlUwOSEQvF2= NF2wbHkzPC92OD:3NkBp NUPXTnNRTE2VTx?= MnTKZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? Ml\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
NCI-H929  MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G0O|EwOiEQvF2= NXvuO5NnOjRxNEivO|IhcA>? MX;EUXNQ MnXaZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl? NUPIeWFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
HeLa NF;lbnJMcW6jc3WgRZN{[Xl? NH7zSphMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy NVK0OpptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa NV7nbGZrU2mwYYPlJGF{e2G7 Moq3T4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy NXyweo8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O|gxODl6PD;hQi=>
HeLa NHn4fmxMcW6jc3WgRZN{[Xl? NIDjfZNMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6MEC5PEc,OjR5OECwPVg9N2F-
HeLa MUHLbY5ie2ViQYPzZZk> MVjLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6MEC5PEc,OjR5OECwPVg9N2F-
NB4 NX3pb3l{TnWwY4Tpc44hSXO|YYm= NXPOW3Y4Oi53L{WvO{42NzFyIN88US=> M1vrOFI1KGh? MWLEUXNQ NXTHSZdZcW6lcnXhd4ViKHSqZTDlfJBz\XO|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>? NULEdnlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFQ5PzBpPkK0OFg1QDdyPD;hQi=>
CD4+ CD25− T  NEfH[GNHfW6ldHnvckBCe3OjeR?= MlLJNU82KM7:TR?= M2G5WJJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NInoVXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3OlM3OCd-MkS0O|Y{PjB:L3G+
BV-173 MULBdI9xfG:|aYOgRZN{[Xl? M4fYWVAvOjVxMD61M|AvPzVxMTFOwG0> M4npeFQ5Nzd{L{m2JIg> MYlCpHBDWw>? MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NUjS[GhoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
ML-1 NI\IWVJCeG:ydH;zbZMhSXO|YYm= NUi1ZWQ5OC5{NT:wMlUwOC55NT:xJO69VQ>? MmjQOFgwPzJxOU[gbC=> MX1CpHBDWw>? NYnmN4JDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60 M33aNmFxd3C2b4Ppd{BCe3OjeR?= MUiwMlI2NzBwNT:wMlc2NzFizszN NXexOJh4PDhxN{KvPVYhcA>? MmTExsBRSlN? NHjDcXVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
KG-1a MlvQRZBweHSxc3nzJGF{e2G7 MoXCNE4zPS9yLkWvNE44PS9zIN88US=> NYrVZWRGPDhxN{KvPVYhcA>? NEPHNYjDqFCEUx?= MUXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= NXrZe2d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
BV-173 Ml3qSpVv[3Srb36gRZN{[Xl? M{XPW|I2OC93MEDuUS=> M1TxbFQ5KGh? NE\FZ2LDqFCEUx?= NE[3O4JqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M4\4N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
CEM MXTGeY5kfGmxbjDBd5NigQ>? NF7rUFUzPTBxNUCwcm0> NU\pUFhpPDhiaB?= MVJCpHBDWw>? NV;mU2IzcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NYDSN3hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HL-60 NH;PUmxHfW6ldHnvckBCe3OjeR?= NWjDOoNiOjVyL{WwNI5O MnO4OFghcA>? NWT2NlBOyqCSQmO= NIX0ZVBqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NHy3NGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
ML-1 NYPZT|ZCTnWwY4Tpc44hSXO|YYm= MnrkNlUxNzVyMH7N MV:0PEBp NXfaWmdQyqCSQmO= NXzPWZNQcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M4X6eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
DLD-1 NULN[nVHTnWwY4Tpc44hSXO|YYm= MX2yOVAwPTBybl2= MW[0PEBp MXRCpHBDWw>? Mmnx[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? NYKyV21uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HCT-116 NGHPVnhHfW6ldHnvckBCe3OjeR?= MW[yOVAwPTBybl2= M13hPFQ5KGh? NGLWXHfDqFCEUx?= NEe4[mVldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
U937-A/E-9/14/18  NHfMeo5CeG:ydH;zbZMhSXO|YYm= MnLrNE4xOS9yLkGvNU8yOCEQvF2= NVPEXXN2PDhiaB?= NX\aVWRWcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWnG[XRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFA1PTZpPkK0N|AxPDV4PD;hQi=>
HT29 NFywfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXMO|IhcA>? NXT2ZYo{UUN3ME2xOFAxyrFzN{mg{txO MoXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
SW48 NIH6S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrnO|IhcA>? NVTWbpBNUUN3ME2xOU4zyrF4LkKg{txO NGX0XWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO|IxPjF:L3G+
HCT116 NWXie3lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr0V5k4OiCq NHn1N2dKSzVyPUGuO:KyOC52IN88US=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
HepG2 NF\zSVhHfW6ldHnvckBCe3OjeR?= MW[wMlUwOSEQvF2= M3XJSlI1KGh? M13wSGROW09? M{PKSpVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M4LPVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
LS174T MlfZSpVv[3Srb36gRZN{[Xl? NIPFenAxNjVxMTFOwG0> M2TwPFI1KGh? M33CfWROW09? MYPs[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?= M4XNNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
HepG2 M1ftO2Fxd3C2b4Ppd{BCe3OjeR?= MnjsNU8yOC9zMECg{txO NEHPem44KGR? M3zrbWROW09? NVT1UphjcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
LS174T MX\BdI9xfG:|aYOgRZN{[Xl? NIHNSGMyNzFyL{GwNEDPxE1? MUS3JIQ> MXzEUXNQ MlnlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3HV[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
QBC-939 MWrBdI9xfG:|aYOgRZN{[Xl? NUW5dHpROS9zMD:xNFAh|ryP NIPoU3k4KGR? MVLEUXNQ NXHhOXlNcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O|Q9N2F-
U251 MWfBdI9xfG:|aYOgRZN{[Xl? MoKzNU8yOC9zMECg{txO MV63JIQ> NET1PHRFVVOR M{XjTolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MoPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
HL-60 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XXZ|Eh|ryP Ml7nOFghcA>? M2GyVIlv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w M4jRWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MECwN|I1Lz5{NECwNFMzPDxxYU6=
MDA‑MB‑453 MVrGeY5kfGmxbjDBd5NigQ>? MYmwMlIwOSEQvF2= NVPM[5pvPzJiaB?= MoXPZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
HCC1569 NXrZUGlHTnWwY4Tpc44hSXO|YYm= NHP3do8xNjJxMTFOwG0> NV;vOnRkPzJiaB?= M2eyfINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> Mm\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ|OES0NlI5RC:jPh?=
BT‑474 MWHGeY5kfGmxbjDBd5NigQ>? NWLne5VrOC5{L{Gg{txO MYO3NkBp M4TGO4NifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> M1PXRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
AGS NHLwUo5CeG:ydH;zbZMhSXO|YYm= MVe1M|ExNzJyL{WwJO69VQ>? MYK0POKhcMLi MoHXSG1UVw>? NVzPXIdQcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB? M1zRSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NUiyO|g1Lz5{M{W4Nlc5PDxxYU6=
A549 MlnXRZBweHSxc3nzJGF{e2G7 NE\FcmE2NzFyL{KwM|UxKM7:TR?= MmexOFjDqGkEoB?= MX\EUXNQ MXvpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NX;QSGRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PFI4QDRpPkKzOVgzPzh2PD;hQi=>
AGS  M4rGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TKXFUwOTBxMkCvOVAh|ryP M4nxNFQ5yqCqwrC= MUDEUXNQ M{PQSIlv\HWlZYOgS|IwVSCyaHHz[UBienKnc4VCpC=> NGTCNW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W4Nlc5PCd-MkO1PFI4QDR:L3G+
Kasumi-1 MYPBdI9xfG:|aYOgRZN{[Xl? NFi4fogxNjVizszN Ml23OFjDqGkEoB?= MYfk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= Ml;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ|NEmzN|Q5RC:jPh?=
OCI-AML3 NY[2O5FpSXCxcITvd4l{KEG|c3H5 MVSyMlUh|ryP MnO1OFjDqGkEoB?= NVnYO|NJ\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> NWC4RpF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
MV4-11 NVe3fXdXSXCxcITvd4l{KEG|c3H5 NEfnbWczNjVizszN NYfBOZcxPDkEoHlCpC=> M4nBfoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ|NEmzN|Q5RC:jPh?=
NK  M4P5ZWN6fG:2b4jpeJkhSXO|YYm= NWXBSHl2OC5yMj2yNEDPxE1? NX;D[pRQPSCm MWHk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm Mn6xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MkiwPFgoRjJ|M{K4NFg5RC:jPh?=
NK  NWfHXJBuSXCxcITvd4l{KEG|c3H5 M{Dlb|AvODJvMkCg{txO MW[1JIQ> M4P0cIRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|MkiwPFgoRjJ|M{K4NFg5RC:jPh?=
NK  M2fzeWZ2dmO2aX;uJGF{e2G7 NHjrc4wxNjBzLUKwJO69VQ>? M3Xxe|Uh\A>? NWLHWpVl[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN|MkiwPFg9N2F-
MOLT4/DNR MmHKSpVv[3Srb36gRZN{[Xl? NFr3S482KM7:TR?= M37BUVQh\A>? MlHzdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> MknUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O|AoRjJ|ME[wOVcxRC:jPh?=
Jurkat/DOX M3PaUmZ2dmO2aX;uJGF{e2G7 M1GwZVUh|ryP M{fkPVQh\A>? MXLy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> M1;EUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
MOLT4/DNR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK1JO69VQ>? NHy1ZXg1KGR? MVzy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MEW3NEc,OjNyNkC1O|A9N2F-
Jurkat/DOX MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW1JO69VQ>? MljWOEBl MUDy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MkG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O|AoRjJ|ME[wOVcxRC:jPh?=
ccRCC  M{H5UmFxd3C2b4Ppd{BCe3OjeR?= NXLLfm41OC5yMT2xNO69VQ>? NIq3XWM4OiCq NX7zV5RsTE2VTx?= M4e0OIhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? M1XkOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
TNBC  NE\oNVlCeG:ydH;zbZMhSXO|YYm= Mnv2NE4xOS1zMN88US=> MYG3NkBp M{X3cmROW09? M{SzNYhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
A498 MnHGRZBweHSxc3nzJGF{e2G7 NV;1SI9XOC5yMT2xNO69VQ>? NIXzeFk4OiCq MlX3SG1UVw>? NH\meFlqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
KIJ265T NUTMc|h3SXCxcITvd4l{KEG|c3H5 NXnZRWZLOC5yMT2xNO69VQ>? NHX1TVU4OiCq MkPRSG1UVw>? NXnNTnp3cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
MDA-231 M3jP[2Fxd3C2b4Ppd{BCe3OjeR?= NHXobVUxNjBzLUGw{txO NYLtRmFNPzJiaB?= MmnGSG1UVw>? MmDybY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NIDTVXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
BT-20 MnTQRZBweHSxc3nzJGF{e2G7 NEjvRlUxNjBzLUGw{txO MoTjO|IhcA>? MlnOSG1UVw>? MWPpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
U937 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zTcFUuOjBizszN Mn22NlQwPDhxN{KgbC=> MYLpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NI\leGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2O|AzOSd-MkK3OlcxOjF:L3G+
HL60 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm1MVIxKM7:TR?= MnHpNlQwPDhxN{KgbC=> Ml;JbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M{H1XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O|AzOTxxYU6=
U937 NVvv[4g{SXCxcITvd4l{KEG|c3H5 M2LXN|E2KM7:TR?= Mnu4NlQwPDhxN{KgbC=> MXLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NGTvOHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2O|AzOSd-MkK3OlcxOjF:L3G+
HL60 NEm5SJRCeG:ydH;zbZMhSXO|YYm= M2LuWlE2KM7:TR?= MmT6NlQwPDhxN{KgbC=> NHrGOoNqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
LS411N  Ml[4RZBweHSxc3nzJGF{e2G7 NWTLUHVpOC53IN88US=> NXfLdlM4PzJiaB?= MXrpcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? M2DMbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NE[xOlk2Lz5{MkS2NVY6PTxxYU6=
MDA-MB-231 NYraSWR5SXCxcITvd4l{KEG|c3H5 NHPnT3cyOCEQvF2= NX3Dc3BOPDhiaB?= M4LKe5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGjoR4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi4O|Y6Pyd-MkG4PFc3QTd:L3G+
MCF-7  NXvSPJNHSXCxcITvd4l{KEG|c3H5 M4XCelExKM7:TR?= MnrsOFghcA>? NUT4NoRkemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6OEe2PVcoRjJzOEi3Olk4RC:jPh?=
A375 NFLzdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDwWYcxNjVizszN M{G2NVEwPS96IHS= NHHIVoJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NEfu[os9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
SKMEL1 NXj6bY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zsVlAvPSEQvF2= NFLXV4cyNzVxODDk NXPRW|Z7cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NHzHW249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
SKMEL3 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXZbXIxNjVizszN NXTWT|ZVOS93L{ig[C=> MlfBbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL28 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfnfHpwOC53IN88US=> NIO2VHIyNzVxODDk MUPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NYfRSGNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO|k3PjJ{PD;hQi=>
MeWo M4nxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PGTVAvPSEQvF2= NEm5Z3gyNzVxODDk Mli1bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NFn5OnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
B16 NV7tPWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:wMlUh|ryP M2jLOlEwPS96IHS= M1rzRYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M3PGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
Ly 1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETFZ2UzPCCq NGT3dZlKSzVyPUeuN{DPxE1? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 7 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnFXXFZOjRiaB?= MkfwTWM2OD1zMD63JO69VQ>? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6 NVW0Znl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuyOEBp MlT5TWM2OO,:nkKwJO69VQ>? M1GydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKyOEBp Ml\DTWM2OO,:nkKwJO69VQ>? M2[zPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA M{WxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHSS4czPCCq NWnVVWlUUUN3MP-8olIxKM7:TR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 NXK1XYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmyOEBp M3mxTWlEPTExvK6yNEDPxE1? MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 1 NF[x[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf5ZnU1QCCq M3f1WGlEPTB;MD6zOEDPxE1? NILPVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 7 NXzhSW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm0PEBp NGTSS5ZKSzVyPUCuNFI2KM7:TR?= NHTUcFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Su-DHL6 NIjpVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3BVY81QCCq NV;CVld[UUN3MP-8olIxKM7:TR?= NYO2PXhIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 10 NVPPW2lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK5XoVPPDhiaB?= Ml3ETWM2OD1zLkig{txO NG\1WW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
RIVA MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV60PEBp MWjJR|Ux97zgMkCg{txO MkHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL2 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj6eWhZPDhiaB?= MWDJR|UxRTF5LkSg{txO M1T0e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 1 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTyN3Y4OiCq NYCyPZZtUUN3ME2wMlAyKM7:TR?= NX6xeJBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 7 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPLdFNZPzJiaB?= M2OyZWlEPTB;MD6wNVgh|ryP MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT5Z2hYPzJiaB?= NU\Qcmx1UUN3ME2xMlYh|ryP M1fIOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfBbZBvPzJiaB?= Mn;yTWM2OD1zLkKg{txO NUPGclBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
RIVA NXXoNZVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DMWlczKGh? M4\TfmlEPTExvK6yNEDPxE1? MnnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL2 NF\xb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHqO|IhcA>? NE\zTnBKSzVyPUGxMlIh|ryP MlXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
U373-MAGI M{fq[2FvfGm4aYLhcEBie3OjeR?= MUGwMlI2KHSxIEigeW0> MViyJJRwKDd{IHjydy=> M3;UT2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gWVUu\2GpIHzleoVtKGG2IECuNlUhfG9iODD1UUBi\nSncjCyJJRwKDd{IHjyd{BjgSCzUFPSJI1mfGixZB?= MlHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI NXK1fVBmSW62aY\pdoFtKGG|c3H5 M4LkUlAvOjVidH:gPEB2VQ>? NHPjU2IzKHSxIEeyJIhzew>? M2CwOGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4FoKGyndnXsJIF1KDBwMkWgeI8hQCC3TTDh[pRmeiB{IITvJFczKGi{czDifUByWEOUIH3leIhw\A>? NFHYU5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO|I3OCd-MkexNVczPjB:L3G+

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
- 合併
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
- 合併
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL warmed (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
別名 Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04985656 Withdrawn Drug: Pevonedistat|Drug: Decitabine|Drug: Cedazuridine Myelodysplastic Syndromes (MDS) Takeda October 1 2021 Phase 2
NCT04854889 Recruiting Drug: Decitabine Refractory Aplastic Anemia Institute of Hematology & Blood Diseases Hospital April 22 2021 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabine (NSC 127716)を買う | Decitabine (NSC 127716) ic50 | Decitabine (NSC 127716)供給者 | Decitabine (NSC 127716)を購入する | Decitabine (NSC 127716)費用 | Decitabine (NSC 127716)生産者 | オーダーDecitabine (NSC 127716) | Decitabine (NSC 127716)化学構造 | Decitabine (NSC 127716)分子量 | Decitabine (NSC 127716)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID